Wealth Enhancement Advisory Services LLC Acquires 43,194 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Wealth Enhancement Advisory Services LLC raised its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 64.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 110,036 shares of the biotechnology company's stock after purchasing an additional 43,194 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Exelixis were worth $4,063,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Coppell Advisory Solutions LLC bought a new stake in shares of Exelixis during the 4th quarter worth about $25,000. Colonial Trust Co SC lifted its position in Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares during the last quarter. Principal Securities Inc. boosted its holdings in shares of Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares during the period. Crowley Wealth Management Inc. acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $50,000. Finally, Hurley Capital LLC bought a new position in shares of Exelixis during the fourth quarter worth approximately $68,000. 85.27% of the stock is owned by institutional investors.

Insider Activity at Exelixis

In other Exelixis news, CMO Amy C. Peterson sold 72,776 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $45.47, for a total value of $3,309,124.72. Following the sale, the chief marketing officer now owns 465,393 shares in the company, valued at $21,161,419.71. This trade represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Christopher J. Senner sold 100,000 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $46.00, for a total value of $4,600,000.00. Following the completion of the transaction, the chief financial officer now owns 967,842 shares of the company's stock, valued at $44,520,732. The trade was a 9.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 458,113 shares of company stock valued at $21,024,817. 2.82% of the stock is owned by insiders.

Wall Street Analyst Weigh In

EXEL has been the subject of several recent research reports. JMP Securities boosted their price target on Exelixis from $47.00 to $50.00 and gave the company a "market outperform" rating in a research note on Monday. UBS Group reissued an "underperform" rating on shares of Exelixis in a report on Thursday, April 17th. Benchmark restated a "neutral" rating on shares of Exelixis in a research note on Monday. Stifel Nicolaus raised their price target on shares of Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $43.22.

Exelixis Trading Up 1.3%

NASDAQ EXEL traded up $0.58 on Friday, hitting $43.67. 3,523,842 shares of the company's stock were exchanged, compared to its average volume of 2,445,232. The stock has a 50-day moving average of $40.92 and a 200-day moving average of $37.27. The stock has a market cap of $11.91 billion, a price-to-earnings ratio of 19.85, a P/E/G ratio of 0.87 and a beta of 0.28. Exelixis, Inc. has a 52 week low of $21.82 and a 52 week high of $49.62.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.